Zura Bio (ZURA) to Release Earnings on Thursday

Zura Bio (NASDAQ:ZURA) is expected to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Zura Bio to post earnings of ($0.19) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Friday, November 7, 2025 at 9:30 AM ET.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. On average, analysts expect Zura Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zura Bio Trading Up 0.3%

Shares of ZURA opened at $3.78 on Thursday. Zura Bio has a 1 year low of $0.97 and a 1 year high of $4.85. The stock has a 50 day simple moving average of $2.86 and a 200-day simple moving average of $1.85. The stock has a market cap of $245.78 million, a PE ratio of -5.40 and a beta of 0.25.

Analyst Ratings Changes

A number of analysts have weighed in on ZURA shares. Chardan Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Zura Bio in a research report on Tuesday, September 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research note on Tuesday, October 14th. Oppenheimer cut their price target on shares of Zura Bio from $17.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, August 15th. Finally, HC Wainwright dropped their price objective on shares of Zura Bio from $3.00 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $11.60.

Institutional Investors Weigh In On Zura Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC acquired a new stake in Zura Bio in the 1st quarter valued at about $72,000. Bank of America Corp DE lifted its holdings in Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after buying an additional 9,966 shares in the last quarter. Jane Street Group LLC acquired a new position in Zura Bio during the 2nd quarter worth $113,000. Finally, JPMorgan Chase & Co. raised its position in shares of Zura Bio by 78.7% during the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after acquiring an additional 2,052,732 shares during the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.